De Novo device
APO-Easy Genotyping kit
Firalis SA · Neurologic Disease Risk Assessment Molecular Test (SFC, Class II) · First FDA decision Jun 12, 2025, newest Jun 12, 2025Alzheimer's disease and dementia
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "APO-Easy Genotyping"
MAUDE reports
0
Brand "APO-Easy Genotyping", since 2015
PubMed studies
0
Mentioning "APO-Easy Genotyping"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing APO-Easy Genotyping kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- APO-Easy Genotyping kitNew device typeDe Novo
DEN240032 · Decided Jun 12, 2025 · 356 days after receipt
Device type: Neurologic Disease Risk Assessment Molecular Test (SFC) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLocal determinationIn effectL39044WPS Insurance CorporationUpdated Jun 18, 2026
- MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLocal determinationIn effectL39038CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLocal determinationIn effectL39001Noridian Healthcare Solutions, LLCUpdated Jan 26, 2026
- MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLocal determinationIn effectL38988Palmetto GBAUpdated Jun 25, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "APO-Easy Genotyping", any status and sponsor, newest update first.
No registered device study names "APO-Easy Genotyping".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "APO-Easy Genotyping", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SFC
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "APO-Easy Genotyping"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.